Key points are not available for this paper at this time.
The clinical use of immune checkpoint inhibitors is expanding rapidly. Oncology practitioners will therefore be required to recognize and manage irAEs in a growing patient population. Early recognition and treatment are essential to prevent patient morbidity and mortality, and adherence to established algorithms is recommended.
Building similarity graph...
Analyzing shared references across papers
Loading...
Friedman et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d900b749e640f9cad1800e — DOI: https://doi.org/10.1001/jamaoncol.2016.1051
Claire F. Friedman
Tracy Proverbs‐Singh
Michael A. Postow
JAMA Oncology
Cornell University
Memorial Sloan Kettering Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...